Alkem Laboratories

Alkem Laboratories shares rises 9% after USFDA report

Alkem Laboratories shares rise 9% after USFDA report:

To begin with, today, the share value of the Alkem Laboratories increased above 9% in the intraday trade. When the US drug regulator, USFD provided the EIR survey report, after that the company shares raised. 

The USFDA provided the establishment inspection on the company’s Baddi unit in Himachal Pradesh. The US drug regulator surveyed from Feb 17th to Feb 21st in Alkem Labs. 

Also, the company received approvals for Dabigatran Etexilate Mesylate from USFDA. The company shares reached its 52-week highest value of Rs 2,720 per eq share on 19th Feb 2020. Similarly, its shares declined to its 52-week lowest value of Rs 1,660.35 per eq share on 28th Jun 2019. 

Presently, the company shares trading with a loss of 9.31% from its 52-week highest value and with a gain of 48.57% from its 52-week lowest value. 

Alkem Laboratories Ltd shares trading with a gain of 93.50 points reached 2,480.00 INR with 3.92% up. Its previous close at 2,386.50 INR on the National Stock Exchange. Alkem Laboratories Ltd shares outstanding with 119,565,000.

Besides, the Sensex and Nifty trading with a bullish trend today (March 13th), The Sensex trading with a gain of 1,325.34 points reached 34,103.48 with 4.04% up. Whereas Nifty trading with a gain of 365.05 points reached 9,955.20 with 3.81% up.

Related posts

Stock Market Update February 4th Sensex and Nifty

Stock Investor

Media Shares on June 4th; Inox Leisure jumped almost 17%

Tarun

Stock Market May 18th Update Sensex and Nifty

Stock Investor